0
The impact of the first dose of the COVID-19 vaccines
The first national population-level study has shed light on the effect of the first dose of the COVID-19 vaccine. The…
Browsing: Disease Area > Viral
0
One drug to rule them all?
Thapsigargin, a promising broad-spectrum antiviral, has proven effective for use against SARS-CoV-2, as well as the influenza A and respiratory…
0
Natural immunity to COVID-19: how long and how strong?
Two recent papers from Public Health England (PHE; London, UK) and Rockefeller University (NY, USA) have shed new light on the duration and quality of protection provided…
0
A nasal spray a day could keep COVID-19 away
Hands, face, space. These are the three tools available to everyday citizens to prevent the spread of COVID-19; the simple…
0
Peak times: the worst years in human history
Throughout 2020, several occasions have prompted the urge to declare that “we’ve hit rock bottom. The only way is up!”…
0
Everything we know about the UK’s novel, emergent strain of COVID-19
As a new COVID-19 strain emerges in the southeast of England that appears to be more infectious than previous strains, what do…
0
How has COVID-19 impacted research?
Discover the vast impacts of the COVID-19 pandemic on the lab research community: from funding cuts, to PhD students changing…
0
Pfizer/BioNTech COVID-19 vaccine approved for use by UK regulator
Pfizer and BioNTech’s COVID-19 vaccine has been approved for use by the UK’s regulator, MHRA, making it the first COVID-19…
0
What are the advantages of the Oxford—AstraZeneca COVID-19 vaccine?
While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly…
0
Moderna’s COVID-19 vaccine demonstrates 94.5% efficacy
Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s…